MedTrace Logo

Continuation Study for Latozinemab

NCT06111014 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-01-21

No results posted yet for this study

Summary

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Conditions

Interventions

DRUG

Latozinemab

All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks

Sponsors & Collaborators

  • Alector Inc.

    lead INDUSTRY

Principal Investigators

  • Study Lead · Alector Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-08
Primary Completion
2025-09-01
Completion
2026-01-07
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • France
  • Germany
  • Italy
  • Netherlands
  • Portugal
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06111014 on ClinicalTrials.gov